Biosens
São Leopoldo
About Biosens
Biosens is transforming the $75B diagnostic market with its Intelligent Point-of-Care Testing (iPOCT) platform, bridging the critical gap between central lab accuracy and bedside speed. While traditional diagnostic journeys take 24 to 48 hours, ou bSens Platform delivers actionable results in under 30 minutes, 100x faster than current standards. The platform leverages a structural cost breakthrough in graphene manufacturing (down 90% since 2018) to replace expensive legacy "gold strip" technology with affordable, high-sensitivity sensors enhanced by AI analysis. Key Highlights: - Clinically Proven: Validated 95% correlation with gold-standard central lab equipment. - Operational ROI: Proven to reduce hospital patient Length-of-Stay (LOS) by 2.5 hours per visit, delivering immediate efficiency gains. - Traction: Endorsed by the President of the World Stroke Organization and validated via an initial PT/INR rollout. Biosens is de-risking the future of diagnostics, enabling immediate clinical decisions and "Actionable Care" at the point of need.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Total funding: $540.6K
- Funding stage: Seed
- Last round: Pre-Seed (Feb 2025)
- Website: biosens.tech
- Phone: [email protected]
Industries & Categories
Advanced Materials, Biotechnology, Genetics, Health Care, Health Diagnostics
Social Profiles
Canonical: https://fsome.com/organization/biosens-148334 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.